63results about How to "Reduce the size of cerebral infarction" patented technology

The invention relates to application of nicotinamide riboside to preparing medicine for treating cerebral ischemic diseases. The application has the advantages that influence of the nicotinamide riboside on cerebral infarction areas of cerebral ischemic models formed in the brains of rats due to artery electrocoagulation occlusion is studied, the cerebral infarction areas can be obviously reduced by nicotinamide riboside administration as proved by the study, obvious cerebral ischemic protection effects can be realized by the nicotinamide riboside as shown by the study, brain injury due to cerebral ischemia can be prevented and treated, and accordingly the nicotinamide riboside has a broad application prospect in the aspects of preparing related medicine for cerebral ischemic injury and / or cerebral infarction.

The present invention relates to total ovateleaf holly saponin for treating coronary heart disease, angina, apoplexy and other cardiac and cerebral vascular diseases, its medicine composition and extracting process. Ovateleaf holly bark is extracted with alcohol, and the extract is added with water and centrifuged to obtain precipitate and supernatant. The precipitate is alcohol reflux extracted,and the extract is treated through filtering, filtrate concentrating, drying and other steps to obtain the first part of total saponin. The supernatant is treated through concentrating, centrifuging,water washing of the precipitate and drying to obtain the second part of total saponin. These two parts of total saponin are merged to obtain the total ovateleaf holly saponin, which may be added with supplementary material and further treated to obtain various kinds of oral preparations and injection.

The invention relates to a compound for treating cerebral infarction. The invention further relates to a preparation method of the compound and an application of the compound for preparing a drug for treating the cerebral infarction. The compound can significantly reduce thrombosis generated after rat vein ligation, and can obviously reduce an area of the cerebral infarction of a rat with middle cerebral artery occlusion. Therefore, the compound can prevent the thrombosis, can facilitate thrombolysis, and can be used in prevention and treatment of the cerebral infarction such as cerebral thrombosis and cerebral embolism.

The prostaglandin A1 is an endogenous active substance obtained by means of conversion of cell membrane lipid in vivo, it can obviously reduce neuronal injury due to ischemia, in the animal experiment is can reduce cerebral infarction area by above 40%, in particular, the administration after ischemia is still effective, it can not be obtained by general medicine in treating apoplexy. Said prostaglandin A1 is small in toxicity, safe, and has a certain therapeutic effect in creating other nervous retrograde diseases, such as Parkinson's disease, Huntington's chorea and senile dementia, etc.

The invention relates to application of nicotinamide riboside to preparing medicine for treating cerebral ischemic diseases. The application has the advantages that influence of the nicotinamide riboside on cerebral infarction areas of cerebral ischemic models formed in the brains of rats due to artery electrocoagulation occlusion is studied, the cerebral infarction areas can be obviously reduced by nicotinamide riboside administration as proved by the study, obvious cerebral ischemic protection effects can be realized by the nicotinamide riboside as shown by the study, brain injury due to cerebral ischemia can be prevented and treated, and accordingly the nicotinamide riboside has a broad application prospect in the aspects of preparing related medicine for cerebral ischemic injury and / or cerebral infarction.

The invention discloses hirudo polypeptide with functions of antithrombus and brain nerve cell protection and application of the hirudo polypeptide, and relates to the fields of traditional Chinese medicine, natural medicine and health care products. The structure of the hirudo polypeptide is presented as a formula I, human umbilical vein endothelial cell expressing vascular hemophilia factor (vWF) and a plasminogen activator inhibitor-1(PAI-1) can be significantly lowered at the low concentration of the hirudo polypeptide, the survival rate of nerve cells after oxygen and glucose deprivationis increased, platelet aggregation in vitro is inhibited, the plasma recalcification time is prolonged, formation of thrombi in vivo is reduced, neurobehavior after cerebral infarction of a rat is improved, encephaledema is relieved, the area of cerebral infarction is reduced, the toxicity is low, good application prospects are achieved, and the hirudo polypeptide can be used for preparing medicine or health care products for treating or adjuvant therapy of cardiovascular and cerebrovascular diseases such as atherosclerosis, thrombi and cerebral post-stroke nerve function deficit. The formulaI is NH2-Leu-D-Leu-Ser-Gly-Val-R whitmantide A: R=D-Leu-Gly-COOHwhitmantide B: R=D-Leu-Gly-Gly-COOH whitmantide C: R=COOH.